Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.89)
# 3,611
Out of 4,711 analysts
58
Total ratings
29.41%
Success rate
-23.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $3.80 | +400.00% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $4.99 | +320.84% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $1.38 | +262.32% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $6.71 | +138.45% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $10 | $1.36 | +635.29% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $13.07 | +91.28% | 2 | May 14, 2024 | |
| ALRN Aileron Therapeutics | Maintains: Buy | $9 → $19 | $1.75 | +985.71% | 2 | Apr 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $0.40 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $200 | $3.99 | +4,912.53% | 1 | Feb 8, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $1.50 | +366.67% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.28 | +338.60% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $0.14 | +2,020.14% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.63 | +852.23% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.20 | +354.55% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.75 | +13,614.29% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $14 | $0.71 | +1,867.40% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.85 | +9,311.76% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.74 | +321.94% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.97 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.99 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.99 | +506.06% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $4.52 | +364.60% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $300 | $0.57 | +52,624.08% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $4.37 | +746.68% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 | $0.93 | +2,054.48% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $701.85 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $68.84 | +29.29% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $135.42 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $1.55 | +64,416.13% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.84 | +18,160.87% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.75 | +213.04% | 1 | Mar 19, 2020 |
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $3.80
Upside: +400.00%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $4.99
Upside: +320.84%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $1.38
Upside: +262.32%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $6.71
Upside: +138.45%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $10
Current: $1.36
Upside: +635.29%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $13.07
Upside: +91.28%
Aileron Therapeutics
Apr 18, 2024
Maintains: Buy
Price Target: $9 → $19
Current: $1.75
Upside: +985.71%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.40
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $200
Current: $3.99
Upside: +4,912.53%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.50
Upside: +366.67%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $2.28
Upside: +338.60%
Sep 22, 2023
Initiates: Buy
Price Target: $3
Current: $0.14
Upside: +2,020.14%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.63
Upside: +852.23%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $2.20
Upside: +354.55%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.75
Upside: +13,614.29%
Apr 28, 2023
Maintains: Buy
Price Target: $8 → $14
Current: $0.71
Upside: +1,867.40%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.85
Upside: +9,311.76%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $4.74
Upside: +321.94%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.97
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.99
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $0.99
Upside: +506.06%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $4.52
Upside: +364.60%
May 6, 2022
Initiates: Buy
Price Target: $300
Current: $0.57
Upside: +52,624.08%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $4.37
Upside: +746.68%
Nov 8, 2021
Upgrades: Buy
Price Target: $20
Current: $0.93
Upside: +2,054.48%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $701.85
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $68.84
Upside: +29.29%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $135.42
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $1.55
Upside: +64,416.13%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.84
Upside: +18,160.87%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $5.75
Upside: +213.04%